Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cyclacel Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cyclacel Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Cyclacel Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cyclacel Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cyclacel Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cyclacel Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cyclacel Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Cyclacel Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cyclacel Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cyclacel Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cyclacel Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cyclacel Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cyclacel Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Cyclacel Pharmaceuticals, Inc. Snapshot 5 Cyclacel Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Cyclacel Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Cyclacel Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Cyclacel Pharmaceuticals, Inc. - Pipeline Products Glance 12 Cyclacel Pharmaceuticals, Inc. - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Cyclacel Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Cyclacel Pharmaceuticals, Inc. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Cyclacel Pharmaceuticals, Inc. - Drug Profiles 16 sapacitabine 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 seliciclib 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 sapacitabine + seliciclib 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CYC-065 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CYC-140 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CYC-800 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule to Inhibit CDKs for HIV/AIDS, Autoimmune Disorders and Inflammation 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Cyclacel Pharmaceuticals, Inc. - Pipeline Analysis 26 Cyclacel Pharmaceuticals, Inc. - Pipeline Products by Target 26 Cyclacel Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 28 Cyclacel Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 29 Cyclacel Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 30 Cyclacel Pharmaceuticals, Inc. - Recent Pipeline Updates 31 Cyclacel Pharmaceuticals, Inc. - Dormant Projects 38 Cyclacel Pharmaceuticals, Inc. - Locations And Subsidiaries 39 Head Office 39 Other Locations & Subsidiaries 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables Cyclacel Pharmaceuticals, Inc., Key Information 5 Cyclacel Pharmaceuticals, Inc., Key Facts 5 Cyclacel Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Cyclacel Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Cyclacel Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Cyclacel Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 Cyclacel Pharmaceuticals, Inc. - Phase III, 2014 12 Cyclacel Pharmaceuticals, Inc. - Phase II, 2014 13 Cyclacel Pharmaceuticals, Inc. - Phase I, 2014 14 Cyclacel Pharmaceuticals, Inc. - Preclinical, 2014 15 Cyclacel Pharmaceuticals, Inc. - Pipeline by Target, 2014 27 Cyclacel Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 28 Cyclacel Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 29 Cyclacel Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 30 Cyclacel Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 31 Cyclacel Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 38 Cyclacel Pharmaceuticals, Inc., Other Locations 39 Cyclacel Pharmaceuticals, Inc., Subsidiaries 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.